NEW YORK (GenomeWeb News) – Beckman Coulter today said that it would pay for the $800 million acquisition of Olympus' diagnostics business through a combination of around $300 million in Beckman Coulter stock and $500 million in newly issued debt.

The firm finished the year with roughly $120 million in cash and cash equivalents and around $900 million in long-term debt. However, Beckman said today that it does not anticipate a change in its current investment grade ratings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.